dm+d

Unassigned

New Medicines

ExblifepUrinary tract infection

Information

Exblifep
New molecular entity
Allecra Therapeutics
Allecra Therapeutics

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Cephalosporins, carbapenems and other beta-lactams (05.01.02)
Extended-spectrum β-lactamase inhibitor
The population eligible to receive this difficult to estimate and may vary according to local resistance patterns. In England (2018/19), ~190,000 hospital admissions were for complicated urinary tract infections, including pyelonephritis and sepsis due to gram-negative bacteria. [11]
Urinary tract infection
Serious, hospital acquired, gram-negative multi drug-resistant infections in combination with cefepime (a 4th generation cephalosporin antibiotic)
Intravenous